Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory‐syncytial‐virus‐related infection in cystic fibrosis children less than 2 years of age?
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- November 2012
has subject area
- 1103 Clinical Sciences (FoR)
- 1114 Paediatrics and Reproductive Medicine (FoR)
- 1117 Public Health and Health Services (FoR)
- Antibodies, Monoclonal, Humanized (MeSH)
- Antiviral Agents (MeSH)
- Cystic Fibrosis (MeSH)
- Hospitalization (MeSH)
- Humans (MeSH)
- Infant (MeSH)
- Palivizumab (MeSH)
- Pediatrics (Science Metrix)
- Respiratory Syncytial Virus Infections (MeSH)